Products

Have an Emergency?

For urgent assistance, please contact emergency response services.

Call: 911

Product Questions?

Questions, comments or concerns about Rising Pharmaceuticals products? Contact one of our trusted professionals today.

Call (800) 521-5340
info@risingpharma.com

Compare Products

Compares to the labeled active ingredients in Reference Brand. The trademark or tradename referenced is NOT registered, owned or licensed by Rising Pharmaceuticals, Inc. or its affiliates.

Indicated in the treatment of fungal infections.

Voriconazole Tablets Voriconazole Tablets

Voriconazole Tablets

Compare to: Vfend® Tablets*
Strength: 50mg | 200mg
* Vfend® is a registered trademark of Pfizer Ireland Pharmaceuticals.
This information has been designed as a quick reference. It is intended as a reference source only and not for prescribing or dispensing product. The appropriate approved prescribing information should be consulted. Images viewed herein may appear different than they do when viewing them live because of computer and/or photographic distortion. In addition, over time, some images and information for a particular product may change. For the most up-to-date product information, please contact your pharmacist or physician.

VORICONAZOLE is indicated for use in patients 12 years of age and older in the treatment of the following fungal infections:

 

1.1 Invasive Aspergillosis

In clinical trials, the majority of isolates recovered were Aspergillus fumigatus. There was a small number of cases of culture-proven disease due to species of Aspergillus other than A. fumigatus.

 

1.2 Candidemia in Non-neutropenic Patients and the Following Candida Infections: Disseminated Infections in Skin and Infections in Abdomen, Kidney, Bladder Wall, and Wounds.

 

1.3 Esophageal Candidiasis

.

 

1.4 Serious Fungal Infections Caused by Scedosporium apiospermum (Asexual Form of Pseudallescheria boydii) and Fusarium spp. Including Fusarium solani, in Patients Intolerant of, or Refractory to, Other Therapy.

.

Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). Therapy may be instituted before the results of the cultures and other laboratory studies are known. However, once these results become available, antifungal therapy should be adjusted accordingly.